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Introduction: Cancer vaccination has been researched as a means of treating and preventing 
cancer, but successful translational efforts yielding clinical therapeutics have been limited. 
Numerous reasons have been offered in explanation, pertaining both to the vaccine formulation, 
and the clinical trial methodology used. This study aims to characterize the tumor vaccine clini-
cal trial landscape quantitatively, and explore the possible validity of the offered explanations 
including the translational obstacles posed by the current common endpoints.
Methods: We performed a detailed cross-sectional and longitudinal analysis of tumor vaccine 
trials (n=955) registered in the US Clinical Trials database.
Results: The number of tumor vaccine trials initiated per annum has declined 30% since a 
peak in 2008. In terms of vaccine formulation, 25% of trials use tumor cell/lysate preparations; 
whereas, 73% of trials vaccinate subjects against defined protein/peptide antigens. Also, 68% of 
trials do not use vectors for antigen delivery. Both these characteristics of tumor vaccines have 
remained unchanged since 1996. The top five types of cancer studied are: melanoma (22.6%); 
cervical cancer (13.0%); breast cancer (11.3%); lung cancer (9.5%); and prostate cancer (9.4%). 
In addition, 86% of the trials are performed where there is established disease rather than pro-
phylactically, of which 67% are performed exclusively in the adjuvant setting. Also, 42% of 
Phase II trials do not measure any survival-related endpoint, and only 23% of Phase III trials 
assess the immune response to vaccination.
Conclusion: The clinical trial effort in tumor vaccination is declining, necessitating a greater 
urgency in identifying and removing the obstacles to clinical translation. These obstacles may 
include: 1) vaccination against a small range of antigens; 2) naked delivery of antigen; 3) inves-
tigation of less immunogenic cancer types; and 4) investigation in the setting of established 
disease. In addition, the prevalence of late phase failure may be due to inadequate assessment 
of survival-related endpoints in Phase II trials. The clinical trial development of tumor vaccines 
should include mechanism-based translational endpoints, as well as the discovery of immune 
biomarkers with which to stratify, monitor, and prognosticate patients.
Keywords: cancer vaccination, cancer prevention, clinical trials, translational trial endpoints, 
immunotherapy
Introduction
Numerous lines of evidence suggest that tumor cells can be recognized and eliminated 
by the immune system.1 On April 29, 2010, sipuleucel-T (Dendreon Corporation, 
Seattle, WA, USA) received US Food and Drug Administration approval for use 
in minimally symptomatic castration-resistant prostate cancer.2,3 This was the first 
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therapeutic cancer vaccine to obtain the US Food and Drug 
Administration approval, a landmark success in the field of 
cancer vaccines, and – at the same time – a reminder of the 
hitherto low therapeutic yield4 of the field. In the context 
of the recent successes of immunomodulatory strategies 
in Phase II and Phase III trials,5,6 it is questionable whether 
cancer vaccines represent an optimal approach for inducing 
greater immunological control of established disease. It can 
be argued that a cancer vaccine will have greater efficacy 
if antigen presentation and the afferent arm of the immune 
system are impaired, while the immunomodulatory strategies 
directed at the T-cell checkpoints and signaling will be more 
effective if the efferent arm of the immune system, espe-
cially T-cell function, is impaired.1,7 A definitive answer that 
instructs clinical translational efforts8 is some years away.
Over the years, numerous reviews have examined the 
obstacles in translating vaccinations that show promise in 
preclinical research into clinical practice. To understand to 
what extent these obstacles are reflected in the clinical trial 
effort as a whole, we characterized the trial landscape by 
analyzing the registered trials on the US trial database (http://
www.clinicaltrials.gov). We also investigate if the current trial 
methodology includes the translational research endpoints 
that can inform vaccine development in the future.
These aforementioned obstacles can be broadly divided 
into two areas: 1) the nature of the vaccination approach; and 
2) the existing clinical trial methodology.9
The therapeutic intervention in cancer vaccine trials 
consists of a particular formulation of tumor-associated 
antigens (TAAs) delivered together with adjuvant(s). There 
remains considerable uncertainty as to the optimal formula-
tion of TAAs. Irradiated tumor cells or tumor cell lysates have 
been suggested to be superior antigen formulations, as they 
stimulate an immune response against diverse tumor antigens 
making immune escape less likely, compared to the formula-
tions containing one or a few recombinant TAAs.10
It is also important to consider the growing evidence for 
the necessity of stimulating cytotoxic T-lymphocytes (CTLs) 
to produce a tumor response.11 CTLs express the cluster of 
differentiation 8 (CD8) T-cell receptor (TCR) coreceptor and 
are major histocompatibility complex class I-restricted.12 
Consequently, this suggests that TAAs need to be delivered 
packaged – eg, in viral vectors – as opposed to naked, or 
alternatively pulsed into antigen presenting cells (APCs) ex 
vivo before infusion. 
Besides the antigen formulation, there is similarly little 
clarity as to the optimal adjuvants.4,13 Classically, adjuvants 
stimulate APC maturation, inducing the expression of 
costimulatory molecules and proinflammatory cytokines, 
which are necessary for the complete activation of T-cells.10 
Increasingly, with the characterization of immune check-
points that prevent a spontaneously effective antitumor 
immune response in cancer patients, eg, the engagement of 
T-cell cytotoxic T-lymphocyte antigen 4 and programmed 
death 1 (PD-1) in the immunosuppressive tumor microen-
vironment, adjuvants may more broadly include biologicals 
that relieve these checkpoints, such as ipilimumab and niv-
olumab, respectively.14,15
Besides the actual vaccination approach, another broad 
area of criticism is the existing clinical trial methodology. 
Both the suitability of patient enrollment criteria used in 
cancer vaccine trials – as well as the methods of assessing the 
therapeutic effects of the vaccine – are thought to be impli-
cated in low translational yields from cancer vaccine trials.
Some tumors – for instance, melanomas and clear cell 
renal cell carcinomas – are considered more immunogenic 
than others, as evidenced by the tumors being frequently 
infiltrated by the CD8+ T-lymphocytes, which correlates 
with favorable prognosis, and occasionally undergoing 
spontaneous regression.14,16–21 These tumor types may be 
more amenable to immunotherapy, with tumor vaccination 
at least serving to trigger the generation of an antitumor 
immune response in the proportion of patients who fail to 
do so spontaneously.22 Thus, the clinical trial efforts focused 
on other tumor types less tractable to immunotherapy could 
explain, in part, the failures of translational efforts.4,14
In advanced disease, multiple redundant mechanisms of 
immune escape are present in the tumor microenvironment, 
and there may be a global systemic dysfunction of T-cells 
as well, perhaps due to chronic nonproductive antigenic 
stimulation.16,23 This may explain poor vaccine efficacy in 
advanced cancers. Maybe cancer vaccines should be mainly 
trialled in the prophylactic or, at the very least adjuvant, 
setting.8,23,24 Cancers with well-established precursor lesions 
– eg, colonic adenomas and pancreatic intraepithelial 
neoplasia – may be good candidates for prophylactic vac-
cination, as they allow a high-risk group to be targeted for 
vaccination.25,26
Another area of intense discussion concerns the suit-
ability of trial endpoints, which were originally formu-
lated to assess the efficacy of cytotoxic chemotherapies. 
Immune responses have different kinetics from cytotoxic 
chemotherapies. They may also appear differently in the 
conventional trial assessment methods, for instance, the 
infiltration of the tumor by lymphocytes leading to appar-
ent radiological progression.9,27 This calls into question the 
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validity of survival measures, such as the radiologically 
assessed progression free survival (PFS) being used as the 
primary endpoint of clinical trials, in spite of its acceptance 
by regulatory authorities.28
Many of the aforementioned reasons proffered to explain 
the poor therapeutic yield of tumor vaccines are based on a 
careful consideration of preclinical data as well as the pub-
lished results of certain clinical trials. It remains an open 
question, whether such analyses are valid across the entire 
spectrum of cancer vaccine interventional trials, so as to have 
sufficient explanatory power to account for the limited trans-
lational success of the field in general. It is also still uncertain 
whether these analyses have encouraged, or at least corre-
spond with, changes across the field. Consequently, these 
analyses will be greatly complemented by a cross-sectional 
and longitudinal study of the tumor vaccine clinical trial 
landscape, which we have undertaken and report here.
Materials and methods
Database creation and analysis
This study is a cross-sectional and longitudinal study of 
interventional cancer vaccine trials registered on the  Clinical 
 Trials Database (http:// www.clinicaltrials.gov). It has been 
conducted and reported according to the Strengthening 
the Reporting of Observational Studies in Epidemiology 
(STROBE) criteria.29 On June 19, 2013, using the advanced 
search function, trials with the terms “cancer” in their list 
of conditions, and “vaccine” in their list of interventions, as 
well as registered as being of an “interventional” study type, 
were selected. Interventional studies refer to those in which 
an intervention of any type, including drugs,  procedures, 
and rehabilitation strategies, was investigated, as opposed to 
purely observational studies.30 Study details were downloaded 
as datasets for review using Microsoft Excel  (Microsoft 
Corporation, Redmond, WA, USA). 
All studies were manually checked to ensure that 
they were trials of cancer vaccines in the prevention or 
therapy of cancer. This led to the exclusion of 43 trials in 
which the primary condition being investigated was not 
cancer, eg, influenza vaccinations in children with cancer 
(NCT00022035), as well as the exclusion of a further 78 
trials in which the intervention was not a cancer vaccine per 
se, eg, the Bacillus Calmette–Guérin vaccine for bladder 
cancer (NCT00427570). All suitable trials registered before 
2013 were included, yielding a total of 955 trials for analysis 
(Figure 1).
The data that were downloaded into Microsoft Excel were 
not edited. As a result, a proportion of the trials was missing 
certain data fields. Incomplete registration details are a known 
limitation of trial database entries.31 The respective trials were 
excluded from the relevant parts of the analysis,31 leading to 
a total trial count of ,955 for most subsections. Total trial 
counts are always specified for each analysis performed. For 
 certain analyses, such as the clinical setting of vaccination, 
the downloaded datasets provided insufficient information. 
In these cases, the online registration entry of the trial on the 
Clinical Trials Database was referred to for further details. 
For the analysis of enrollment numbers, comparison with 
interventional cancer trials in general, ie, all  interventions, 
was needed. The relevant trial data were downloaded from 
the Clinical Trials Database on June 19, 2013 with the 
 following criteria: 1) study type – interventional studies; 
and 2)  conditions –  cancer. This yielded a total of 30,859 
trials. These data were not subject to manual review.
Statistical analysis
All averages are given as mean ± standard error of mean, 
unless otherwise stated. For selected longitudinal series, 
linear regression analysis was performed. For comparison 
of means and medians, the Student’s t-test and the Wilcoxon 
rank-sum test were performed, respectively. Also, P,0.05 
was taken to indicate statistical significance.
Results
Overall trial characteristics
Of the 955 trials included in the overall analysis, data for 
the trial start date and the trial primary completion date 
were available for 935 trials and 776 trials, respectively. 
A longitudinal analysis of trial start dates (Figure 2A) reveals 
a decline in the number of clinical trials initiated, with the 
count declining 30% from a peak of 87 in 2008 to 61 in 
2012. On a per annum basis, the number of vaccine trials 
decreased on average by 6.5 each year from 2008 onward 
(P,0.01). The corresponding peak in trial completion is in 
2013 (Figure 2A). This is broadly in line with a calculated 
mean trial duration of 4.0±0.1 years (n=776). In contrast, the 
counts of trial start dates for the nonvaccine interventional 
cancer vaccine trials have stayed approximately constant from 
2008–2012 (P=0.68). Relative to 2008, the trial counts for 
subsequent years are significantly different (P=0.02), when 
comparing between vaccine and nonvaccine trials.
Phase data were available for 887 Phase I–Phase III 
 trials. There are similar numbers of Phase I and Phase II 
trials, which together account for 88% of trials conducted 
(Figure 2B). This relative proportion of clinical trials has 
stayed fairly constant since 1996 (Figure 2C).
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Studies on clinicaltrials.gov that meet the following criteria on June 19, 2013. 
1) Study type – interventional studies;
2) Conditions – cancer; 
 3) Interventions – vaccine
(n=1,102)
Trials manually reviewed for correctness with regard to above search criteria.
Trial disease is not cancer.
(n=43)
Trials in which the  intervention is not a
cancer vaccine, ie, does not contain
tumor antigens or antigens from cancer
causative organisms, eg, BCG vaccine
for bladder cancer.
(n=78)
Cancer vaccine trials registered on clinicaltrials.gov up to June 19, 2013.
(n=981)
Trials first registered
between January 1, 2013–June 19, 2013.
(n=26)
Cancer vaccine trials included in overall analysis.
(n=955)
Figure 1 Flow diagram of database creation and manual review of trials.
Note: 955 trials in total are included in the overall analysis.
Abbreviation: Bcg, Bacillus calmette–guérin.
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Nature of vaccination approach
A cross-sectional analysis of the antigen formulation used in 
the 955 trials was performed as shown in Figure 3. In 75% 
of the trials, the tumor antigens vaccinated against were a 
relatively small number of specified protein or carbohy-
drate antigens; whereas, in 25% of the trials, patients were 
exposed to a wide range of tumor-associated antigens via 
administration of tumor cells or their lysates (Figure 3A). 
This proportion has remained relatively stable across time, 
with an annual mean of 24.2%±2.0% from 1996–2012 
(Figure 3B).
The majority (68%) of the trials involved the adminis-
tration of naked antigen (Figure 4A). This proportion has 
stayed relatively constant across the time, with an annual 
mean of 68.9%±1.8% from 1996 –2012 (Figure 4B). The 
remaining 32% of the trials adopted vectors that com-
prised: dendritic cells (20%); viral vectors (9%), espe-
cially  poxviruses and adenoviruses; and naked nucleic 
acids (4%), including unpackaged deoxyribonucleic acid, 
 ribonucleic acid, and plasmids. Notably, even though only 
1% of all the trials employed anti-idiotype vaccines, 33% 
of the trials in which carbohydrate antigens were vaccinated 
against used anti-idiotype vaccines. This reveals the utility 
of the anti-idiotype vaccines in specifying carbohydrate 
antigens, which are generally less immunogenic than 
protein antigens.
By an inspection of the data, we observed that almost 
all trials included the administration of adjuvants in the 
intervention under study. However, a wide range of adju-
vants was used, rendering systematic categorization impos-
sible and inappropriate. To demonstrate this spectrum of 
adjuvants, we chose to examine those employed in Phase 
III trials initiated within the last 5 years (n=40; Table S1), 
as these experimental vaccines are likely to have the great-
est near-term clinical significance. As shown in Table 1, a 
total of 15 vaccines were studied in 40 trials. These vac-
cines utilized eight different adjuvants. There was, thus, 
no apparent preference for any adjuvant. Even among the 
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four human papillomavirus (HPV) vaccines analyzed, all 
of which  comprised viruslike particles that were made up 
of L1 capsid protein of various HPV strains, different adju-
vants were used. For example, one used alum (aluminum 
 hydroxide); another two, amorphous aluminum hydroxy-
phosphate sulfate; and a final one, a combination of alum 
and monophosphoryl lipid A. 
Existing trial methodology:  
patient characteristics
In addition, 1,178 instances of various cancers were studied 
across 955 trials; 28 trials did not specify, or incompletely 
specified, the type of cancer studied. Of the remaining 
927  trials, 860 (93%) studied one cancer type. Many of 
the  cancers that did not adequately specify cancer type 
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phases is relatively constant over time. analysis restricted to years with at least ten registered trials.
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had – instead – inclusion criteria based on the tumor antigen 
expression, eg, overexpression of vaccine antigen.
The distribution of cancer types across trials is shown 
in Figure 5A, with the nine cancer types studied in 5% or 
more of trials being reflected. The top five cancer types 
were: melanoma (22.6%); cervical cancer (13.0%); breast 
cancer (11.3%); lung cancer (9.5%); and prostate cancer 
(9.4%). The other cancer type thought to be immunogenic, 
renal cancer, was studied in only 36 (3.8%) trials. While the 
predominance of melanoma is striking, there is a statistically 
significant decrease in the percentage of trials in which it is 
studied (Figure 5B).
Data on the primary purpose were available for 933 of 
the 955 trials included. Overall, the majority of trials inves-
tigated therapeutic cancer vaccines, although a minority of 
the trials (13%) was performed in the preventive setting. 
Most of the preventive trials involved cancer types with a 
suggested or proven infectious etiology, especially HPV in 
cervical cancer (Figure 6B). Since 1996, there is a trend 
toward a higher proportion of preventive cancer vaccine 
trials (Figure 6B).
Of the 803 therapeutic trials performed, we sought to 
determine whether they were performed in the adjuvant 
setting, or in the clinical context of unresected, and likely 
advanced and thus unresectable, disease. We excluded trials 
that considered premalignant conditions (14) or hemato-
logical malignancies (110), as well as trials that provided 
insufficient information to determine the clinical context 
of vaccination (161). This left 518 trials for analysis. This 
analysis revealed that in 67% of trials, the vaccine was 
administered exclusively in the adjuvant setting, a proportion 
that has stayed relatively constant over time (Figure 6C).
Existing trial methodology: 
endpoints
Considering only therapeutic (as oppose to preventive) trials, 
endpoint data were available for 637 of the 803 therapeutic 
 trials. There is a decrease in the proportion of the trials  assessing 
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Table 1 Vaccines investigated in Phase iii trials commencing between 2008 and 2012, (n=40)
Vaccine Description Adjuvants Setting NCT #
algenpantucel-l alpha-1,3-galactosyltransferase- 
expressing allogeneic pancreatic  
tumor cell vaccine
none adjuvant ncT01072981
Belagenpumatucel-l contains nsclc tumor cells TgF-β2 antisense adjuvant ncT00676507
e75 peptide +  
gM-csF vaccine
hla a2/a3-restricted her-2/neu 
peptide vaccine
gM-csF Prevention ncT01479244
emepepimut-s liposomal BlP25 vaccine MPl adjuvant ncT01015443
Fowlpox-Psa- 
TricOM vaccine
recombinant fowlpox vaccine  
encoding prostate-specific antigen
TricOM (B7.1, icaM-1  
and lFa-3)
adjuvant ncT01322490
gV1001 contains telomerase peptide gM-csF adjuvant ncT00925548
hPV 16/18 l1 viruslike  
particle vaccine
Different formulation from cervarix 
developed by Xiamen innovax Biotech
alum Prevention ncT01735006
hPV 16/18 l1 viruslike 
particle/as04 vaccine
as04 (alum +MPl) Prevention ncT00637195 
ncT01381575 
ncT00799825 
ncT00849381 
ncT00779766 
ncT01190189 
ncT00929526 
ncT01249365 
ncT01627561 
ncT01277042 
ncT00811798 
ncT00652938 
ncT01190176 
ncT00877877 
ncT00947115 
ncT01418937 
ncT00937950
hPV vaccine V503 contains l1 capsid proteins for  
nine hPV strains
amorphous aluminum  
hydroxyphosphate sulfate
Prevention ncT01651949 
ncT01047345 
ncT00943722 
ncT01254643 
ncT01073293 
ncT00988884
iMa901 contains ten renal cell carcinoma 
associated peptide antigens
gM-csF nonadjuvant ncT01265901
POl-103a Contains purified antigens from  
melanoma cell lines
alum adjuvant ncT01546571
Polyvalent antigen-Klh  
conjugate vaccine
contains globo h, gM2 ganglioside, 
Tn-MUc1, TF, and sTn
OPT-821 (purified,  
natural saponin)
adjuvant ncT00693342
Quadrivalent hPV  
(types 6, 11, 16, 18)  
recombinant vaccine
amorphous aluminum  
hydroxyphosphate sulfate
Prevention (4), 
precancerous (1)
ncT00964210 
ncT01245764 
ncT01461096 
ncT01375868 
ncT00496626
racotumomab anti-P3 antibody idiotype  
monoclonal antibody 1e10
alum adjuvant ncT01460472
Vaccinia-Psa- 
TricOM vaccine
recombinant vaccinia vaccine  
encoding prostate-specific antigen
TricOM (B7.1, icaM-1  
and lFa-3)
adjuvant ncT01322490
Abbreviations: hPV, human papillomavirus; gM-csF, granulocyte macrophage colony-stimulating factor; MPl, monophosphoryl lipid a; TgF-β, transforming growth factor beta; 
ncT, national clinical Trial; nsclc, non-small-cell lung cancer.
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the immune response, eg, through antibody titers and T-cell 
enzyme-linked immunosorbent spot assays, declining from 
78% of Phase I trials to 23% of Phase III trials (Figure 7A).
Examining the use of survival-related endpoints, such 
as overall survival (OS) and PFS, more closely (Figure 7B), 
42% of the Phase II trials did not include any of these 
endpoints in the assessment of therapeutic efficacy. In the 
Phase III trials, 17% of trials did not measure OS. Instead, 
they relied on other survival-related endpoints, such as PFS 
(Figure 7B).
Trial size was also assessed in terms of enrollment numbers. 
Enrollment numbers were available for 838 of the 955 trials, 
but suspended (nine), withdrawn (61), and terminated (20) tri-
als were further excluded due to incomplete enrollment, thus 
yielding 748 trials in this analysis. Data were analyzed by phase, 
with data from mixed-phase trials discarded. As expected, trial 
enrollment numbers increase with the trial phase (Figure 7C). 
Comparing trial enrollment numbers of the cancer vaccine tri-
als with those of cancer trials in general (n=25,638), trial size 
is significantly smaller in Phase I cancer vaccine trials, but 
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significantly larger in Phase III and Phase IV cancer vaccine 
trials, compared to all cancer trials. The former may be due to 
the reduced toxicity of cancer vaccines compared to cytotoxic 
chemotherapies or even targeted molecular inhibitors,3 while 
the latter is likely to reflect the delayed effect of the cancer 
vaccines mentioned earlier, which necessitates larger patient 
populations to achieve adequate statistical power.
Discussion
In this study, we have analyzed the characteristics of all the 
cancer vaccine trials registered in the US Clinical  Trials 
Database before 2013, corresponding to 955 trials. The 
chosen database is the most comprehensive trial database 
available.32 Such a methodology has been previously applied 
by ourselves and others to characterize the trial landscape in 
traumatic brain injury,30 as well as nephrology33 and oncol-
ogy in general.34
Overall trial characteristics
A longitudinal analysis of cancer vaccine trials revealed a 
peak in 2008 followed by a decline (Figure 2A). While this 
could be due to the global reasons across the cancer research 
sector, or perhaps the entire clinical trial landscape, this is 
made unlikely by the fact that a similar peak in trial count 
could not be observed when nonvaccine interventional cancer 
trials were analyzed. Instead, this finding suggests that there 
is indeed a real and significant decline in the translational 
effort for cancer vaccines; this is probably a reflection of the 
poor therapeutic yield of the field as earlier discussed and 
suggests that a greater urgency is necessary in identifying 
and addressing the underlying causes.
An analysis of the trials by phase obtained a distribution 
that was not dissimilar to that obtained by others who have 
analyzed cancer interventional trials.35 These data are in line 
with previous data that had shown the response rate in early 
phase cancer vaccine trials to be similar to the lower end of the 
response rates observed in early phase interventional cancer 
trials.4 This suggests that, in their current design, Phase II 
cancer vaccination trials excessively overestimate therapeutic 
efficacy. Consequently, although it has been argued that the 
selection of trial endpoints underestimates the benefit of the 
cancer vaccines,4,27 the precise effects of trial endpoints on 
response rates are likely to be more complex.
Nature of vaccination approach
Our analyses of antigen formulation revealed that 25% of 
the trials included a wide range of tumor-associated anti-
gens (Figure 3), and 32% of the trials included a delivery 
vector (Figure 4). This lends quantitative support to earlier 
suggestions that the contributing factors to the poor effi-
cacy of the cancer vaccines include (i) vaccination against 
too few antigens, thus making tumor escape possible,10 as 
well as (ii) the failure to deliver antigens into the cytosol of 
antigen-presenting cells so as to enable major histocompat-
ibility complex class I presentation and thus a cytotoxic 
T-lymphocyte response.11 
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Interestingly, the previously mentioned proportions have 
remained approximately constant over time. This suggests 
that – despite calls to modify the antigen formulation – the 
approach to clinical trials remains conservative on these 
questions. This may be due to significant logistical difficulties 
in the production of such vaccines, in spite of their theoretical 
advantages, most notably for autologous vaccine formulations 
that require the preparation of patient-specific vaccines from 
their tumor material and/or peripheral blood APCs.11
We have observed that a wide spectrum of adjuvants 
was used, indicating that adjuvants account for a sizable 
proportion of variation between vaccine formulations 
(Table 1). This observation implies that the optimal adjuvant 
is still uncertain, and it also supports earlier observations 
of a nontargeted approach across the field toward adjuvant 
selection, which may be hindering the identification of the 
optimal adjuvant.36 Indeed, the necessity of carefully test-
ing the effect of adjuvants was highlighted by a recent trial, 
which showed that the addition of granulocyte macrophage 
colony-stimulating factor to an melanoma tumor cell vaccine 
reduced T-cell responses and OS at 2 years.36 Thus, the lack 
of a systematic approach to adjuvant testing may contribute 
to the poor efficacy of the cancer vaccines in general.
Existing trial methodology
The most frequently studied cancers are melanoma and 
cancers of the cervix, breast, lung, and prostate (Figure 5A). 
These data are broadly in line with that of Dayoub and Davis, 
who performed a cross-sectional analysis of the therapeutic 
tumor vaccine trials registered from January–May 2011.37
The frequency with which breast, lung, and prostate 
cancers are studied is likely to reflect their high incidence 
and contribution to annual mortality,37 while the study of 
melanoma and cervical cancers is likely to be driven – at 
least in part – by their perceived tractability to vaccination 
strategies, due to the immunogenicity of melanomas and 
the infectious etiology of cervical cancers. While renal 
 cancers have been considered immunogenic as well, the low 
frequency with which they have been studied may be due 
to disappointing results from a number of adjuvant clinical 
trials of autologous renal cell carcinoma vaccines in the late 
1990s to the early 2000s.8
This analysis of the cancer types studied provides some 
support for the argument that the translational failures of 
cancer vaccines are due to efforts being directed at the com-
mon cancers less amenable to vaccine therapy. Further sup-
port can be obtained from the observation that  – apart from 
sipuleucel-T  – the other cancer vaccines receiving approval 
are targeted at cervical cancer, malignant melanoma, or renal 
carcinoma.
Interestingly, however, the proportion of trials involving 
melanoma patients is on the decrease. This may reflect a 
more nuanced and less empirical understanding of cancer 
immunogenicity, for instance through the identification of 
more TAAs38 across different cancer types. An additional 
explanation for this relative decline of melanoma vaccine 
trials could be the recent success of immune checkpoint 
inhibition, eg, ipilimumab,6 in treating metastatic melanoma. 
Both these developments may have resulted in translational 
efforts being refocused away from melanoma, which may 
subsequently lead to a further dilution and decline of thera-
peutic success in the field.
Also, this study has revealed that a relatively small 
proportion of the translational effort has been directed 
at preventive cancer vaccines. Most of these vaccines are 
directed against HPV (Figure 6B). Although the propor-
tion of cancer vaccine trials conducted in the preventive 
setting has been increasing, it is doubtful whether this 
overall trend will continue, given the presence of a notice-
able peak in trials initiated in 2007, and the fact that two 
vaccines against HPV strains, Cervarix® (GlaxoSmith-
Kline plc, London, UK) and Gardasil® (Merck & Co, Inc., 
Whitehouse Station, NJ, USA), have already received 
regulatory approval.
Further efforts in the field may be driven by the develop-
ment of vaccines against other infectious agents, for instance, 
Helicobacter pylori (NCT00613665) in the context of gastric 
carcinoma or gastric mucosa-associated lymphoid tissue 
lymphoma. However, the economic drivers of these trans-
lational efforts may be weaker, given the fact that some, if 
not many, of the infectious causes of cancers have a higher 
incidence in poorer countries, eg, H. pylori and Schistosoma 
haematobium.21
For the remaining trials that were conducted with the 
aim of treatment rather than prevention, we have shown that 
67% of the trials assessed vaccine efficacy exclusively in 
the adjuvant setting, with a further 26% including at least 
some patients free of macroscopic disease (Figure 6C). This 
suggests that the lack of therapeutic efficacy of candidate vac-
cines cannot be attributed to the immunosuppressive effects 
of the tumor in situ. The local immunosuppressive effect of 
the stroma in micrometastases, however, is potentially caus-
ative and – in the preclinical setting – is currently actively 
researched. Also, these data cannot exclude the possibility 
that vaccine efficacy is attenuated by immunosuppressive 
effects of the tumor that persist even after resection, as has 
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been demonstrated in a mice melanoma model.39 Indeed, poor 
vaccine responses in the adjuvant setting may even perhaps 
be attributable to the long-term immunosuppressive effects 
of adjuvant cytotoxic chemotherapy,2,40 a valuable question 
that can be addressed in future clinical trial analyses.
With regard to trial endpoints, our data suggest some fur-
ther explanations regarding the use of existing endpoints that 
may contribute to the high rate of late phase failures. First, 
a minority of Phase III trials do not assess OS, but depend 
instead on endpoints, such as PFS and disease-free survival, 
even though several immunotherapies, (eg, sipuleucel-T and 
ipilimumab), have demonstrated increases in OS without 
attendant increases in the PFS or related measures.3 Second, 
in 42% of Phase II trials, no survival-related endpoint was 
measured, suggesting that a significant proportion of candi-
date vaccines enter late phase trials on the basis of radiologi-
cal evidence of tumor response, a surrogate measure that is 
known to be problematic for immunotherapies.41
Most importantly from a translational research point of 
view, this study has also revealed that only a small proportion 
of late phase trials assess the immune response to the tumor 
vaccine under investigation (Figure 7A). We suggest that 
Phase II and especially Phase III trials should include objec-
tive immune response analyses more frequently to facilitate 
translational science and a better understanding of positive 
and negative trial outcomes, especially in the context of a 
high proportion of failed late stage clinical trials. Moreover, 
immunological data from the late phase trials will be vital 
to enabling the optimal use of cancer vaccines in clinical 
practice postlicensing, as given the aforementioned prob-
lems with assessing vaccine response radiologically, some 
surrogate of the clinical benefit is required to prognosticate 
and plan for additional therapies, which may be therapeutic 
or palliative.3
Trial design can be adjusted to take into account the 
logistical demands of immunological endpoint assessment, 
including assessing these endpoints in a subgroup of patients 
to reduce costs or only in selected participating tertiary 
referral centers, where the necessary technical expertise is 
available. Regardless, beginning to assess immunological 
endpoints now will enable the development of the necessary 
clinical trial infrastructure to do so more reliably and cost 
effectively in the future.
Conclusion
By characterizing the landscape of interventional clinical 
vaccine trials, this study has revealed declining numbers 
of trials initiated since 2008; there is a need for greater 
urgency in removing the obstacles to the clinical translation 
of experimental vaccines.
Our data have demonstrated that only in a minority of 
trials are vaccines that incorporate a wide range of tumor 
antigens or utilize vectors for antigen delivery assessed, 
providing quantitative support for the hypotheses that these 
characteristics of experimental vaccines are impeding clini-
cal translation. We have also observed a significant lack of 
consistency in terms of the adjuvants employed in the 
various trials, including Phase III trials – suggesting that 
cancer vaccines, in general, still lack effective adjuvants. 
In terms of the clinical trial methodology, our data reveal 
that while melanoma is the most common cancer studied, 
significant clinical efforts are being directed at common 
cancers not regarded as particularly immunogenic. Also, 
we have confirmed the observation that only a minority of 
cancer vaccines is used prophylactically, predominantly 
HPV vaccines. We have demonstrated that, in addition to 
this, the majority of therapeutic cancer vaccines are trialed 
in the adjuvant setting, suggesting that disease volume has 
little impact on vaccine efficacy. Longitudinally, the overall 
picture is generally one of stasis, with minimal evolution of 
the trial landscape in spite of various calls to the contrary. 
Finally, considering both the finding of a surprisingly high 
proportion of Phase III trials and the observation that 42% of 
Phase II trials did not utilize any survival-related endpoints, 
we suggest that a failure to adequately estimate therapeutic 
efficacy in Phase II trials is contributing, at least in part, to 
the high rate of translational failure in the late phase trials. We 
also note the relative paucity of mechanistic immunological 
endpoints in the Phase III trials, which – if not rectified – is 
likely to hinder translational efforts in the field as well as the 
optimal clinical use of approved vaccines.
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Table S1 Details of Phase iii trials commencing between 2008 and 2012
NCT # Formulation Title First  
received
Start  
year
Primary  
completion
Enrollment Status
ncT01072981 algenpantucel-l immunotherapy study for surgically  
resected Pancreatic cancer
2010 2010 2014 722 recruiting
ncT00676507 Belagenpumatucel-l Phase iii lucanix™ Vaccine Therapy in 
advanced non-small cell lung cancer 
(nsclc) Following Front-line  
chemotherapy
2008 2008 2012 506 active, not 
recruiting
ncT01479244 e75 peptide plus gM- 
csF vaccine
Efficacy and Safety Study of  
neuVaxTM (nelipepimut-s or e75)  
Vaccine to Prevent Breast cancer  
recurrence
2011 2011 2015 700 recruiting
ncT01015443 emepepimut-s cancer Vaccine study for stage iii,  
Unresectable, non-small cell lung  
cancer (nsclc) in the asian  
Population
2009 2009 2016 420 recruiting
ncT00925548 emepepimut-s a study of stimuvax® in combination  
With hormonal Treatment Versus  
hormonal Treatment alone for First- 
line Therapy of endocrine-sensitive  
advanced Breast cancer
2009 2009 2010 42 Terminated
ncT01322490 Fowlpox-Psa-TricOM 
vaccine, Vaccinia-Psa- 
TricOM vaccine
a randomized, Double-blind, Phase 3 
Efficacy Trial of PROSTVAC-V/F +/−  
gM-csF in Men With asymptomatic  
or Minimally symptomatic Metastatic  
castrate-resistant Prostate cancer
2011 2011 2015 1,200 recruiting
ncT01579188 gV1001 study of the Telomerase Vaccine  
gV1001 to Treat Patients With  
inoperable stage iii non-small cell 
lung cancer
2012 2012 2016 600 not yet 
recruiting
ncT01047345 hPV – V503 a study of V503 Vaccine in Females  
12–26 Years of age Who have  
Previously received garDasil™  
(V503-006 aM1)
2010 2010 2011 924 completed
ncT00943722 hPV – V503 a study of V503 in Preadolescents and  
adolescents (V503-002 eXT1 eXT2)
2009 2009 2011 3,074 active, not 
recruiting
ncT01254643 hPV – V503 a study of the safety, Tolerability,  
and immunogenicity of V503  
administered to 9- to 15-Year-Old  
Japanese girls (V503-008)
2010 2011 2013 100 active, not 
recruiting
ncT01073293 hPV – V503 a study of V503 Vaccine given  
concomitantly With rePeVaXTM in  
11 to 15 Year Olds (V503-007 aM1)
2010 2010 2011 1,054 completed
ncT00988884 hPV – V503 a study of V503 given concomitantly 
With MenactraTM and adacelTM in  
11 to 15 Year Olds (V503-005) 
(cOMPleTeD)
2009 2009 2011 1,245 completed
ncT01735006 hPV 16/18 l1 viruslike 
particle vaccine
Efficacy and Immunogenicity Study of  
recombinant human Papillomavirus  
Bivalent Type 16/18 Vaccine
2012 2012 2015 6,000 recruiting
ncT00637195 hPV 16/18 l1 viruslike 
particle/as04 vaccine
immunogenicity and safety of a  
commercially available Vaccine co- 
administered With gsK hPV  
Vaccine (580299)
2008 2008 2009 152 completed
(Continued)
Supplementary material
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Table S1 (Continued)
NCT # Formulation Title First  
received
Start  
year
Primary  
completion
Enrollment Status
ncT01381575 hPV 16/18 l1 viruslike 
particle/as04 vaccine
evaluation of immunogenicity and  
safety of Two 2-dose human  
Papillomavirus (hPV) Vaccine  
schedules in 9–14 Year Old girls
2011 2011 2014 1,428 active, not 
recruiting
ncT00799825 hPV 16/18 l1 viruslike 
particle/as04 vaccine
safety study of gsK Biologicals’  
human Papillomavirus Vaccine  
in 580299/008 subjects From  
canada or the Us
2008 2009 2012 1,000 completed
ncT00849381 hPV 16/18 l1 viruslike 
particle/as04 vaccine
safety study of gsK Biologicals’  
human Paillomavirus Vaccine in  
580299/008 subjects from Brazil,  
Taiwan or Thailand
2009 2009 2012 1,239 completed
ncT00779766 hPV 16/18 l1 viruslike 
particle/as04 vaccine
Efficacy, Immunogenicity and Safety  
of gsK Biologicals’ hPV gsK  
580299 Vaccine in healthy chinese 
Female subjects
2008 2008 2011 6,051 active, not 
recruiting
ncT01190189 hPV 16/18 l1 viruslike 
particle/as04 vaccine
safety evaluation of the gsK-580299 
Vaccine in Women From the control 
group in the Primary ncT00294047  
study
2010 2011 2015 600 recruiting
ncT00929526 hPV 16/18 l1 viruslike 
particle/as04 vaccine
Extension Study of the Efficacy of  
the gsK 580299 Vaccine in Japanese 
Women Vaccinated in the Primary  
ncT00316693 study
2009 2009 2011 752 completed
ncT01249365 hPV 16/18 l1 viruslike 
particle/as04 vaccine
The safety evaluation of the gsK- 
580299 Vaccine in Women From  
the control group in the Primary  
ncT00294047 study
2010 2011 2015 465 recruiting
ncT01627561 hPV 16/18 l1 viruslike 
particle/as04 vaccine
safety and immunogenicity of  
glaxosmithKline (gsK) Biologicals’  
human Papillomavirus Vaccine in  
healthy Female children
2012 2012 2016 1,000 recruiting
ncT01277042 hPV 16/18 l1 viruslike 
particle/as04 vaccine
study to assess immune responses  
and safety of the gsK-580299  
Vaccine in healthy Women (26 to  
45 Years)
2011 2011 2012 1,212 completed
ncT00811798 hPV 16/18 l1 viruslike 
particle/as04 vaccine
safety study of gsK Biologicals’ hPV 
Vaccine (gsK-580299) in healthy  
Female subjects
2008 2009 2010 92 completed
ncT00652938 hPV 16/18 l1 viruslike 
particle/as04 vaccine
evaluation of immunogenicity and  
safety of human Papillomavirus (hPV) 
Vaccine co-administered With another 
Vaccine in healthy Female subjects
2008 2008 2009 744 completed
ncT01190176 hPV 16/18 l1 viruslike 
particle/as04 vaccine
gynaecological Follow-up of a subset 
of hPV-015 (ncT00294047) study  
subjects
2010 2011 2018 1,500 recruiting
ncT00877877 hPV 16/18 l1 viruslike 
particle/as04 vaccine
evaluation of long-term  
immunogenicity and safety of a human  
Papillomavirus (hPV) Vaccine in  
healthy Female subjects
2009 2009 2010 529 active, not 
recruiting
ncT00947115 hPV 16/18 l1 viruslike 
particle/as04 vaccine
evaluation of long-term  
immunogenicity and safety of a human 
Papillomavirus (hPV) Vaccine in  
healthy Female subjects
2009 2009 2010 666 active, not 
recruiting
(Continued)
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Table S1 (Continued)
NCT # Formulation Title First  
received
Start  
year
Primary  
completion
Enrollment Status
ncT01418937 hPV 16/18 l1 viruslike 
particle/as04 vaccine
safety evaluation of a human  
Papillomavirus (hPV) Vaccine in healthy 
Female control subjects From the  
gsK hPV 023 study
2011 2012 2014 220 recruiting
ncT00937950 hPV 16/18 l1 viruslike 
particle/as04 vaccine
gynaecological Follow-up of a subset  
of 580299/008 (ncT 00122681)  
study subjects
2009 2009 2014 2,500 recruiting
ncT01651949 hPV vaccine V503 Multivalent hPV (human  
Papillomavirus) Vaccine study in  
16- to 26-Year Old Men and  
Women (V503-003 aM5)
2012 2012 2014 2,500 recruiting
ncT01265901 iMa901 iMa901 in Patients receiving sunitinib 
for advanced/Metastatic renal cell  
carcinoma
2010 2010 2014 330 active, not 
recruiting
ncT01546571 POl-103a study of a Melanoma Vaccine in  
stage llb, llc, and iii Melanoma  
Patients
2012 2012 2016 1,059 recruiting
ncT00693342 Polyvalent antigen-Klh 
conjugate vaccine
Vaccine Therapy and OPT-821 or  
OPT-821 alone in Treating Patients  
With Ovarian epithelial cancer,  
Fallopian Tube cancer, or Primary  
Peritoneal cancer in complete  
remission
2008 2008 2012 0 Withdrawn
ncT01245764 Quadrivalent hPV  
(types 6, 11, 16, 18)  
recombinant vaccine
garDasilTM study in healthy  
Females Between 9 and 26 Years of  
age in sub-saharan africa (V501-046)
2010 2011 2013 250 completed
ncT01461096 Quadrivalent hPV  
(types 6, 11, 16, 18)  
recombinant vaccine
evaluating the effectiveness of the  
Quadrivalent human Papillomavirus  
(hPV) Vaccine at Preventing anal  
hPV infection in hiV-infected Men  
and Women
2011 2012 2015 564 recruiting
ncT01375868 Quadrivalent hPV  
(types 6, 11, 16, 18)  
recombinant vaccine
effect of Vaccination in Patients With  
recurrent respiratory Papillomatosis
2011 2011 2017 50 recruiting
ncT00496626 Quadrivalent hPV  
(types 6, 11, 16, 18)  
recombinant vaccine
an immunogenicity and safety study  
of gardasil® in chinese subjects  
(V501-030) (cOMPleTeD)
2007 2008 2009 600 completed
ncT00964210 Quadrivalent hPV  
(types 6, 11, 16, 18)  
recombinant vaccine
Protecting Young special risk Females 
From cervical cancer Through human  
Papilloma Virus (hPV) Vaccination
2009 2008 2010 240 completed
ncT01460472 racotumomab immunotherapy With racotumomab  
in advanced lung cancer
2011 2010 2015 1,082 recruiting
Abbreviations: hPV, human papillomavirus; ncT, national clinical Trial; gM-csF, granulocyte macrophage colony-stimulating factor.
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